Triple Combination Therapy for HDV Reduces RNA
A combination therapy of lonafarnib, ritonavir, and Lambda appeared safe for up to 6 months in patients with chronic hepatitis D, according to data presented at The Liver Meeting 2019. The triple combination therapy also led to high rates of RNA decline.
In the phase 2a open label LIFT HDV study, 26 patients with HBV and chronic HDV received lonafarnib 50 mg with ritonavir 100 mg orally twice daily, and Lambda 180 µg subcutaneously once a week.
There was a decline in median HDV RNA in 21 patients from baseline to 12 weeks (3.36 vs 4.74 log IU/mL; P < 0.0001). Undetectable HDV RNA was achieved in 5 patients and HDV RNA below the lower limit of quantification was achieved in 5 patients.
At 24-weeks, there was a further decline in the HDV RNA decline of 16 patients (3.18; P < 0.0001). Undetectable HDV RNA was achieved in 7 patients and HDV RNA below the lower limit of quantification was achieved in 3 patients
Koh C. Abstract LO8. Presented at: The Liver Meeting; Nov. 7-12, 2019; Boston.